Sandoz

Sandoz, a Novartis company and a global leader in generic pharmaceuticals launch of first biosimilar Zarxio (filgrastim-sndz). Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA).

Sandoz, a global leader in generic pharmaceuticals and a  subsidiary of Novartis, has received approval from the US Food and Drug Administration (FDA) for Glatopa. Glatopa is the first FDA-approved, substitutable generic version of Copaxone^® 20mg, a treatment for relapsing forms of multiple sclerosis. Sandoz, together with Momenta, is proud to be the first company to receive FDA approval for a substitutable generic version of this important therapy.